KinoTeck Therapeutics Co., Ltd

This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).

评估KNT-0916在FGFR2异常不可切除的局部晚期或转移性实体瘤患者中的安全性、耐受性和疗效 。